• Home
  • Mental Health
  • Depression
  • Meditation
  • Stress Disorders
  • Anxiety
  • Mental Illness
  • Contact Us
No Result
View All Result
Natural Element
  • Home
  • Mental Health
  • Depression
  • Meditation
  • Stress Disorders
  • Anxiety
  • Mental Illness
  • Contact Us
No Result
View All Result
Natural Element
No Result
View All Result

FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder

January 16, 2023


  • Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United States.

PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ — Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved Rykindo® (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

Rykindo® was developed by Luye Pharma on its microsphere technology platform. The drug is administered via intramuscular injection once every two weeks and delivers the active ingredient, risperidone, via long-acting and extended-release microsphere technology.

Schizophrenia and bipolar disorder are both severe mental disorders. There were 40 million sufferers of bipolar disorder worldwide in 2019, and currently around 24 million schizophrenia patients[1]. In the U.S., the estimated prevalence of schizophrenia and related psychotic disorders ranges between 0.25% and 0.64%[2], while an estimated 4.4% of U.S. adults experience bipolar disorder at some point in their lives[3].

“Mental disorders including schizophrenia and bipolar disorder not only seriously affect the physical and mental health of patients, but also impose a heavy burden on their families and the society. Rykindo® is our first new drug developed in-house and approved for marketing in the U.S., demonstrating our long-standing commitment to serving patients around the world with innovative therapies,” said Yang Rongbing, President of Luye Pharma Group. “At Luye Pharma, we continue to enrich our product portfolio in the CNS field by focusing on the unmet needs of patients, and we look forward to making further contributions to the mental health community by providing better care and better services to those in need.”

Rykindo® was approved for marketing in China in 2021 for the treatment of schizophrenia. The development of Rykindo® in Europe is progressing, with plans to launch the drug in more countries and regions around the world.

The central nervous system is a key therapeutic area of focus for Luye Pharma. The company has built a robust product portfolio in the field, including a number of commercialized products and drug candidates, covering multiple diseases such as depression, Parkinson’s disease, schizophrenia, bipolar disorder and Alzheimer’s disease.

About Rykindo®

Developed by Luye Pharma, Rykindo® is administered via intramuscular injection once every two weeks and delivers its active ingredient, risperidone, via long-acting and extended-release microsphere technology.

Rykindo® is an atypical antipsychotic indicated:

  • for the treatment of schizophrenia in adults.
  • as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Rykindo® is not approved for use in patients with dementia-related psychosis.

Contraindications

Rykindo® should not be administered to patients with known hypersensitivity to risperidone, paliperidone, or to any components in Rykindo®.

Warnings and Precautions

  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased risk of cerebrovascular adverse reactions (e.g., stroke, transient ischemia attack).
  • Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring.
  • Tardive Dyskinesia: Discontinue treatment if clinically appropriate.
  • Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain.
  • Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. Long-standing hyperprolactinemia, when associated with hypogonadism, can lead to decreased bone density in males and females.
  • Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular disease or cerebrovascular disease, and risk of dehydration or syncope.
  • Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood cell counts (CBC) in patients with a history of clinically significant low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Rykindo® if clinically significant decline in WBC occurs in the absence of other causative factors.
  • Potential for Cognitive and Motor Impairment: Use caution when operating machinery.
  • Seizures: Use cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.
  • Priapism: Priapism has been reported during postmarketing use of other risperidone products. Severe priapism may require surgical intervention.

Adverse Reactions

The most common adverse reactions in patients with schizophrenia (≥ 5%) were headache, parkinsonism, dizziness, akathisia, fatigue, constipation, dyspepsia, sedation, weight increase, pain in extremity, and dry mouth.

The most common adverse reactions in patients with bipolar disorder were (5% in monotherapy trial) weight increased and (≥ 10% in adjunctive therapy trial) tremor and parkinsonism.

Please see full Prescribing Information at https://www.luye.cn/lvye_en/rykindo.pdf

About the Clinical Trials of Rykindo®

Clinical trials of Rykindo® include:

  • An open-label, single-ascending dose pharmacokinetic and safety study of LY03004 following escalating single intramuscular injection in stable patients with schizophrenia or schizoaffective disorder (NCT02055287)
  • A randomized, open-label, parallel-group study to assess the relative bioavailability of LY03004 and Risperdal® Consta® at 25 mg following multiple intramuscular injections in stable patients with schizophrenia or schizoaffective disorder (NCT02091388)
  • A randomized open-label pharmacokinetic study of LY03004 compared to Risperdal® Consta® following a single intramuscular injection at 25mg or 50mg in stable patients with schizophrenia and/or schizoaffective disorder (NCT02186769)

About Schizophrenia

Schizophrenia is a mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Although the course of schizophrenia varies among individuals, schizophrenia is typically persistent and can be both severe and disabling[2]. Schizophrenia affects approximately 24 million people or 1 in 300 people worldwide[1]. Estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%[2].

About Bipolar Disorder

Bipolar disorder is a mental illness that causes unusual shifts in mood, energy, activity levels, concentration, and the ability to carry out day-to-day tasks[4]. 40 million people experienced bipolar disorder worldwide in 2019[1]. An estimated 4.4% of U.S. adults experience bipolar disorder at some time in their lives[3].

Bipolar disorder is a category that includes three different diagnoses: bipolar I, bipolar II, and cyclothymic disorder. Bipolar I disorder is diagnosed when a person experiences a manic episode. During a manic episode, people with bipolar I disorder experience an extreme increase in energy and may feel on top of the world or uncomfortably irritable in mood. Some people with bipolar I disorder also experience depressive or hypomanic episodes, and most people with bipolar I disorder also have periods of neutral mood.[5]

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets – China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

References

1. Mental disorders. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed in January 2023

2. Schizophrenia. National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/schizophrenia. Accessed in January 2023

3. Bipolar Disorder. National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/bipolar-disorder. Accessed in January 2023

4. Bipolar Disorder. National Institute of Mental Health. https://www.nimh.nih.gov/health/topics/bipolar-disorder. Accessed in January 2023

5. What Are Bipolar Disorders? American Psychiatric Association. https://www.psychiatry.org/patients-families/bipolar-disorders/what-are-bipolar-disorders. Accessed in January 2023

Cision View original content:https://www.prnewswire.com/news-releases/fda-approves-luye-pharmas-rykindo-for-the-treatment-of-schizophrenia-and-bipolar-1-disorder-301721891.html

SOURCE Luye Pharma



Source_link

Share120Tweet75Share30

Related Posts

Speaking with forked tongues
Mental Illness

Speaking with forked tongues

January 27, 2023

— Dissident Voice Bruce Lerro writes on crafting linguistic propaganda by boiling, freezing and muddying language CAN language limit thought? IF A dogmatic belief system can narrow the kind of vocabulary used, can language itself limit the kind of...

Woman arrested in US accused of murdering Saudi student in knife attack
Mental Illness

Woman arrested in US accused of murdering Saudi student in knife attack

January 27, 2023

DUBAI: Although mental health issues present a significant challenge to productivity, a benchmark survey in Saudi Arabia has revealed yawning gaps between the services that human resources departments claim to provide and what employees believe is actually on offer, with...

Surge in Demand for Mental Health Services a Challenge for Providers | Chicago News
Mental Illness

Surge in Demand for Mental Health Services a Challenge for Providers | Chicago News

January 27, 2023

The COVID-19 pandemic has brought mental health issues to the fore. But as more people have been willing to acknowledge their struggles, the provision of mental health services has become a major challenge. Dr. Robert Shulman, director of clinical...

Toronto’s future depends on having a safe TTC
Mental Illness

Toronto’s future depends on having a safe TTC

January 26, 2023

If we let the TTC go down the drain, the whole city won’t be far behind.That’s what’s at stake in the crisis around safety in Toronto, and especially on the subways, streetcars and buses of the Toronto Transit Commission....

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

  • Anxiety (433)
  • Depression (134)
  • Meditation (206)
  • Mental Health (410)
  • Mental Illness (365)
  • Sound Therapy (2)
  • Stress Disorders (244)

Popular

  • Stress Level Of Americans Is Rising Rapidly In 2022, New Study Finds

    Stress Level Of Americans Is Rising Rapidly In 2022, New Study Finds

    302 shares
    Share 121 Tweet 76
  • 4 signs of burnout in your teen– and how to help them through it

    302 shares
    Share 121 Tweet 76
  • How Stress Affects Your Vision

    302 shares
    Share 121 Tweet 76
  • Helpful Resources During Suicide Prevention Month 2022 – My Brain’s Not Broken

    301 shares
    Share 120 Tweet 75
  • Anxiety Success Stories – Revealing Podcast Interview With Marcos Codas

    301 shares
    Share 120 Tweet 75

  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Copyright © 2022 Naturalele.com | All Rights Reserved.

No Result
View All Result
  • Home
  • Mental Health
  • Depression
  • Meditation
  • Stress Disorders
  • Anxiety
  • Mental Illness
  • Contact Us
What Are Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT